For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total revenue | 0 | 718 | 132 | 6,272 |
| Payroll and payroll-related expenses | - | 2,394* | - | - |
| Total direct program expenses | - | 3,874* | - | - |
| Other research and development expenses | - | 321* | - | - |
| Research and development | 11,181 | 6,588 | 5,870 | 6,465 |
| General and administrative | 6,665 | 6,423 | 6,785 | 4,880 |
| Total operating expenses | 17,846 | 13,011 | 12,655 | 11,345 |
| Loss from operations | -17,846 | -12,293 | -12,523 | -5,073 |
| Other income (expense), net | 858 | 21,957 | 365 | 389 |
| Gain before provision for income taxes | -16,988 | 9,663 | -12,158 | -4,684 |
| Provision for income taxes | 0 | 0 | 0 | 0 |
| Net gain | -16,988 | 9,663 | -12,158 | -4,684 |
| Basic EPS | 0 | 9,538.993 | -168.01 | - |
| Diluted EPS | 0 | 9,538.993 | -168.01 | - |
| Basic Average Shares | 0 | 1,013 | 1,250 | - |
| Diluted Average Shares | 0 | 1,013 | 1,250 | - |
Ovid Therapeutics Inc. (OVID)
Ovid Therapeutics Inc. (OVID)